Thrombocytopenia associated with galsulfase treatment

Human and Experimental Toxicology

Volumn 30, Issue 7, 2011, Pages 768-771

  Doǧan, Murat ^a,b   Cesur, Yasar ^a   Peker, Erdal ^a   Oner, Ahmet F ^a   Dogan, Sekibe Zehra ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b Hafiziye Mahallesi K Karabekir Caddesi Ara tirma Hastanesi Arkasi   (Turkey)

Author keywords

galsulfase therapy; mucopolysaccharidosis type VI; thrombocytopenia

Indexed keywords

DIPHENHYDRAMINE; GALSULFASE; GLYCOSAMINOGLYCAN; HEMOGLOBIN; N ACETYLGALACTOSAMINE 4 SULFATASE;

ARTICLE; BLOOD CELL COUNT; CASE REPORT; CHILD; DRUG DOSE REDUCTION; ENZYME REPLACEMENT; FACIES; FOLLOW UP; HUMAN; HURLER SYNDROME; JOINT MOBILITY; LEUKOCYTE; MALE; MAROTEAUX LAMY SYNDROME; MEGAKARYOCYTE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCALP HAIR; THORAX DEFORMITY; THROMBOCYTE; THROMBOCYTOPENIA;

CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 79959735952     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327110379023     Document Type: Article

References (10)

1. El Dib RP, Pastores GM A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase. Biologics 2009 ; 3: 459-468.
2. Azevedo AC, Schwartz IV, Kalakun L., Brustolin S., Burin MG, Beheregaray AP, et al. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet 2004 ; 66: 208-213. (Pubitemid 39232782)
3. Kim KH, Decker C., and Burton BK Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]). Pediatrics 2008 ; 121: 714-717.
4. Harmatz P., Whitley CB, Waber L., Pais R., Steiner R., Plecko B., et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome. J Pediatr 2004 ; 144: 574-580. (Pubitemid 38594756)
5. Harmatz P., Ketteridge D., Giugliani R., Guffon N., Teles EL, Miranda MC, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005 ; 115: 681-689.
6. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006 ; 148: 533-539.
7. Naglazyme (Gasulfase). http://www.naglazyme.com/en/About-NAGLAZYME/ NAGLAZYME-side-effects.aspx. (Accessed date: May 26, 2010 ).
8. European Medicines Agency, http://www.ema.europa.eu/humandocs/PDFs/EPAR/ naglazyme/391047en6.pdf (Accessed date: May 26, 2010 ).
9. Lanzkowsky P. Manual of pediatric hematology and oncology. 4 th ed. California: Elsevier, 2005.
10. Wilson DB Acquired platelet defects. In: Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, and Lux SE (eds) Nathan and Oski's: hematology of infancy and childhood. 7 th ed. Philadelphia: WB Saunders, 2009, p. 1553-1590.